Under the deal, Microsoft will act as a preferred cloud provider for JJMDC’s digital surgery solutions
The Johnson & Johnson Medical Devices Companies (JJMDC) has entered into a strategic partnership with Microsoft to further empower and bolster its digital surgery ecosystem.
JJMDC’s medical technology is used throughout an ecosystem, including next generation robotics, world-class instrumentation, advanced imaging and visualisation, data and analytics, artificial intelligence, machine learning, and digital solutions.
Under the deal, Microsoft will act as a preferred cloud provider for JJMDC’s digital surgery solutions. It will support JJMDC to build its digital surgery platform and internet of things (IoT) device connectivity.
Johnson & Johnson’s medical devices global vice president and group CIO Larry Jones said: “Collaborating with Microsoft will help take our digital approach to the next level as we create a best-in-class, unified platform across our innovative surgical technologies.
“It brings together our collective expertise and is an exciting step towards creating a connected patient journey across the entire care continuum, before, during, and after a procedure.”
Both firms will work together to use Microsoft Cloud, Microsoft 365 and Dynamics 365 platforms in different areas to deliver better performance. Microsoft Cloud consists of Azure, artificial intelligence (AI), and machine learning.
The companies will use AI machine learning and data insights to enhance JJMDC’s patient outcomes, while Azure IoT and Edge Computing technologies will be used to increase JJMDC device connectivity, insights and intelligence.
Using Azure capabilities and services, the pace of digital innovation and transformation across the JJMDC digital surgery ecosystem will be increased.
JJMDC medical affairs, clinical affairs and pre-clinical research global head and digital innovation office leader Dr Peter Schulam said: “We’re excited to collaborate with Microsoft on this important work as we continue to expand our digital surgery assets and capabilities, develop innovative and advanced instrumentation, and make a meaningful clinical difference for customers and patients.”